Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.91 USD
-0.04 (-1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.90 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ORGO 2.91 -0.04(-1.36%)
Will ORGO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ORGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORGO
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
ORGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
Best Momentum Stocks to Buy for January 5th
New Strong Buy Stocks for January 5th
Other News for ORGO
Lake Street starts Organogenesis with Buy on competitive advantages
Organogenesis initiated with bullish view at Lake Street
Organogenesis Shareholders Affirm Governance and Strategy
Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference